
    
      The study consists of 4 periods: 1) Washout Period (if applicable); 2) a Screening Period of
      up to 100 days prior to first dose; 3) a 6 month Treatment Period; and 4) a Post treatment
      Follow-up Period of up to 12 months (if applicable). An electronic diary will be dispensed
      and training provided to record endometriosis-associated pain, uterine bleeding, and
      analgesic medication use for endometriosis-associated pain on a daily basis. Pregnancy
      testing will be performed monthly throughout the study. Subjects will be required to use
      nonhormonal dual contraception during the study, and will be counseled on appropriate and
      effective forms of birth control to promote pregnancy prevention.
    
  